Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
CRISPR Therapeutics AG (NASDAQ: CRSP) closed the day trading at $62.1 down -0.35% from the previous closing price of $62.32. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 2.38 million shares were traded. CRSP stock price reached its highest trading level at $64.19 during the session, while it also had its lowest trading level at $60.5.
Ratios:
For a better understanding of CRSP, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.61 and its Current Ratio is at 16.61. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99. TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 18 ’25 when Kulkarni Samarth sold 13,081 shares for $58.15 per share. The transaction valued at 760,660 led to the insider holds 207,004 shares of the business.
Treco Douglas A bought 20,000 shares of CRSP for $1,140,600 on Aug 06 ’25. The Director now owns 22,000 shares after completing the transaction at $57.03 per share. On Jul 16 ’25, another insider, George Simeon, who serves as the Director of the company, bought 989,812 shares for $52.03 each. As a result, the insider paid 51,499,918 and bolstered with 1,730,179 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5668030464 and an Enterprise Value of 4142236160. For the stock, the TTM Price-to-Sale (P/S) ratio is 148.44 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 108.863 whereas that against EBITDA is -9.473.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.82, which has changed by 0.3272066 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $71.13, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is 8.27%, while the 200-Day Moving Average is calculated to be 35.94%.
Shares Statistics:
Over the past 3-months, CRSP traded about 3.17M shares per day on average, while over the past 10 days, CRSP traded about 2733950 shares per day. A total of 88.38M shares are outstanding, with a floating share count of 86.10M. Insiders hold about 5.33% of the company’s shares, while institutions hold 77.11% stake in the company. Shares short for CRSP as of 1756425600 were 22074375 with a Short Ratio of 6.96, compared to 1753920000 on 23446400. Therefore, it implies a Short% of Shares Outstanding of 22074375 and a Short% of Float of 27.41.
Earnings Estimates
The performance of CRISPR Therapeutics AG (CRSP) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$1.1, with high estimates of $0.16 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.16 and -$7.33 for the fiscal current year, implying an average EPS of -$6.14. EPS for the following year is -$4.54, with 16.0 analysts recommending between -$2.25 and -$6.71.
Revenue Estimates
A total of 23 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $128.26M, while the lowest revenue estimate was $1.76M, resulting in an average revenue estimate of $34.05M. In the same quarter a year ago, actual revenue was $37.31M
